Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2018-12-05 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
2018年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled '2018 年限制性股票激励计划实施考核管理办法' which translates to '2018 Restricted Stock Incentive Plan Implementation Assessment Management Measures'. It details the company's stock incentive plan, including performance assessment criteria, evaluation principles, scope, and procedures related to the restricted stock incentive plan. It is a governance-related document focusing on the company's internal incentive and assessment mechanisms for management and key personnel. There is no financial statement, earnings data, or regulatory filing announcement. It is not an annual or interim report, nor an earnings release or capital update. It is not a proxy solicitation or voting result. The document relates to governance and management policies regarding stock incentives. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 2402 characters, which is not a brief announcement but a detailed policy document, supporting this classification.
2018-12-05 Chinese
中小企业板上市公司股权激励计划草案自查表
Governance Information Classification · 95% confidence The document is a detailed compliance self-checklist related to a company's equity incentive plan, including numerous regulatory and procedural compliance items. It references internal controls, audit opinions, shareholder meetings, and legal compliance related to equity incentives. The content is focused on the governance and regulatory compliance aspects of the equity incentive plan rather than financial results or earnings. There is no indication that this is an annual or quarterly financial report, audit report, or earnings release. It is not a simple announcement or a short notice but a comprehensive compliance document. The document aligns best with governance-related filings, specifically concerning internal rules and governance practices around equity incentive plans. Therefore, the most appropriate classification is Governance Information (CGR).
2018-12-05 Chinese
第六届监事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 13th meeting of the 6th Supervisory Board of Hualan Biological Engineering Inc. It details the approval of a restricted stock incentive plan draft, its implementation assessment methods, and the verification of the incentive recipients list. The document includes voting results and compliance statements but does not contain financial statements or detailed financial data. It is a corporate governance-related announcement about management incentive plans and supervisory board decisions, not a full report or financial disclosure. The document length is short (1700 characters), and it is an official meeting resolution announcement. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2018-12-05 Chinese
独立董事关于第六届董事会第十三次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on the company's 2018 restricted stock incentive plan, discussing compliance with laws, qualifications of incentive recipients, and the scientific and reasonable nature of performance indicators. It is a formal opinion related to board matters and governance but does not contain financial statements or earnings data. It is not an announcement of a report, nor a certification letter. The content focuses on board-level approval and governance of a stock incentive plan, which aligns with Board/Management Information filings.
2018-12-05 Chinese
关于召开2018年第一次临时股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about convening the 2018 first extraordinary general meeting of shareholders for 华兰生物工程股份有限公司. It includes information about the meeting date, voting procedures (both onsite and online), agenda items for shareholder approval, registration details, and proxy authorization forms. The content is focused on informing shareholders about the meeting logistics and voting process rather than reporting financial results or management commentary. It is not an annual report, earnings release, or management discussion. It is not a voting results announcement since it is a notice before the meeting. The document is clearly a meeting notice for a shareholders' meeting, which fits the category of AGM Information (AGM-R). The document length (7447 characters) and detailed procedural content confirm it is the meeting notice itself, not just an announcement of a report publication or a regulatory filing. Therefore, the classification is AGM Information (AGM-R).
2018-12-05 Chinese
第六届董事会第十三次会议决议公告（已取消）
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding the approval of a restricted stock incentive plan and related matters. It details voting results, board decisions, and plans to submit these matters to the shareholders' meeting. It also announces the convening of an extraordinary general meeting (临时股东大会) to discuss these proposals. The document is not a full report like an annual or interim report, nor is it a transcript, audit, or financial supplement. It is a formal announcement of board resolutions and meeting arrangements, which fits the category of Board/Management Information (MANG). The document length is 2584 characters, which is relatively short and focused on board decisions rather than detailed financial data or presentations.
2018-12-05 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.